The winner's circle - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
The winner's circle
While the pharmaceutical industry took a hit and the giants of the industry saw a loss in sales a surprising number of the top pharma companies turned in double-digit growth last year. This report on the world's top 50 companies shows clearly that the industry's elite still features players who know how to hit the bullseye.

Pharmaceutical Technology Europe




The Pharm Exec 50 report for 2008 accounts for prescription drug sales of more than $510 billion. Interestingly, except for Pfizer, GSK, Sanofi-Aventis (numbers one to three, respectively), and Watson (number 50), every company on the list showed positive growth last year, including some solid double-digit performances.




Much of that growth was driven by mergers, of which there were many. Nycomed, for example, almost tripled in size after its purchase of Altana, itself a top 50 company. And because rankings in the Pharm Exec 50 are calculated in US dollars, a number of European companies look better than they might have done. (Roche's prescription drug revenue, for instance, grew by 11% in Swiss francs, but more than 20% in US dollars.)








A key change has been made in the way this year's 50 were assembled. In the past, private companies that did not disclose sales figures were omitted, but this year for the first time estimates are being offered. This mostly affects privately owned European companies, such as Menarini, Servier, and Ratiopharm, though it also means a first-time ranking for Procter & Gamble, whose multi-billion dollar pharmaceutical operation is such a small part of the company that P&G declines to break out the figures by sales of human prescription drugs and vaccines, as reported in annual reports and SEC filings.














Royalty revenue, contract manufacturing, animal health and OTC have not been counted as far as the documents allow. Some accompanying charts are based on figures from IMS health. These are calculated differently, and may disagree with numbers cited in the 50 itself.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What factor do you think will be most significant in 2010 for determining the health of the market for contract manufacturing of active pharmaceutical ingredients?
The global economic recovery
The US economic recovery
Improved credit and financing flow to the small to emerging pharma/bio sector
Less restrictive inventory control by pharmaceutical companies
The level of competition from contract manufacturers in emerging markets
The global economic recovery
40%
The US economic recovery
14%
Improved credit and financing flow to the small to emerging pharma/bio sector
14%
Less restrictive inventory control by pharmaceutical companies
9%
The level of competition from contract manufacturers in emerging markets
24%
View Results
Eric LangerOutsourcing OutlookEric Langer A Bio View of Outsourcing
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Advances in Custom Synthesis
Faiz kermaniSpotlightFaiz Kermani EU pricing dilemmas
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Keep an eye on that cargo
Pharma packs a punch
Another Boost for Vaccines
Rodney Dangerfield and R&D
Federal Spending Freeze Could Threaten Supply-Chain Security
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here